Cancer — Efficacy Study of IL-21 to Treat Metastatic Melanoma
Citation(s)
An Open-label, Dose Escalation Safety and Tolerability Study of Recombinant Human Interleukin-21 (Phase 1) Followed by an Open-label Treatment Study (Phase 2a) in Patients With Stage IV Malignant Melanoma